Radiation dose distributions in normal tissue adjacent to tumors containing 131I or 90Y: The potential for toxicity

Journal of Nuclear Medicine

Volumn 43, Issue 8, 2002, Pages 1110-1114

  Sparks, Richard B ^a   Crowe, Eric A ^a   Wong, Franklin C ^a   Toohey, Richard E ^a   Siegel, Jeffry A ^a  

^a CDE Dosimetry Services Inc   (United States)

Author keywords

Absorbed dose profile; Dosimetry; Radioimmunotherapy; Tissue toxicity; Tumors

Indexed keywords

IODINE 131; YTTRIUM 90;

ARTICLE; CANCER RADIOTHERAPY; HUMAN; MATHEMATICAL MODEL; MONTE CARLO METHOD; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIATION SICKNESS; RADIOIMMUNOTHERAPY;

COMPUTER SIMULATION; HUMANS; IODINE RADIOISOTOPES; MONTE CARLO METHOD; NEOPLASMS; RADIATION DOSAGE; RADIOTHERAPY DOSAGE; YTTRIUM RADIOISOTOPES;

EID: 0036327871     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Radioimmunotherapy of solid cancers: A review
2. 90Y-2IT-BAD-m170 for metastatic prostate cancer
3. 90Y-linked monoclonal MUC-1 antibodies
4. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma
5. 90Y-conjugates: The IEO experience
6. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
7. Law and order of radiation sensitivity: Absolute versus relative